Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S J Rodig

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Cell|May 20, 1998
Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responsesS J Rodig, M A Meraz, J M White, et al.
Leukemia|August 1, 2012
Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cellsJ Etchin, Q Sun, A Kentsis, et al.
Cell|February 9, 1996
Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathwayM A Meraz, J M White, K C Sheehan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 11, 2020
Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomasS Derks, L K de Klerk, X Xu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 2024
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancerA Di Federico, S L Alden, J W Smithy, et al.
Leukemia|July 24, 2015
Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG miceJ Etchin, J Montero, A Berezovskaya, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 16, 2022
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinomaS Scalera, B Ricciuti, M Mazzotta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 25, 2022
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS<sup>G12D</sup>-mutated non-small-cell lung cancerB Ricciuti, J V Alessi, A Elkrief, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 5, 2024
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRAS<sup>G12C</sup> inhibitorsA Di Federico, L Hong, A Elkrief, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Cell|May 20, 1998
Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responsesS J Rodig, M A Meraz, J M White, et al.
Leukemia|August 1, 2012
Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cellsJ Etchin, Q Sun, A Kentsis, et al.
Cell|February 9, 1996
Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathwayM A Meraz, J M White, K C Sheehan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 11, 2020
Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomasS Derks, L K de Klerk, X Xu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 2024
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancerA Di Federico, S L Alden, J W Smithy, et al.
Leukemia|July 24, 2015
Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG miceJ Etchin, J Montero, A Berezovskaya, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 16, 2022
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinomaS Scalera, B Ricciuti, M Mazzotta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 25, 2022
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS<sup>G12D</sup>-mutated non-small-cell lung cancerB Ricciuti, J V Alessi, A Elkrief, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 5, 2024
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRAS<sup>G12C</sup> inhibitorsA Di Federico, L Hong, A Elkrief, et al.
Pageof 1